Department Pharmazie - Arbeitskreis Prof. Dr. F. Bracher
Startseite CUP  |  EDV-Service/Webmail  |  Intranet
Intranet
Seite drucken
BELIEBTE LINKS

Dr. Marco Keller

Kontakt


Department Pharmazie
Zentrum für Pharmaforschung
Butenandtstraße 5-13
D - 81377 München

Büro: C 3.049
Labor: C3.043
Tel.  +49-89-2180-77299, -77295
Fax. +49-89-2180-77171
Email. marco.keller@cup.uni-muenchen.de



Publikationen

M. Keller, A. Wolfgardt, C. Müller, R. Wilcken, F. M. Böckler, S. Oliaro-Bosso, T. Ferrante, G. Balliano, F. Bracher; Arylpiperidines as a new class of oxidosqualene cyclase inhibitors; European Journal of Medicinal Chemistry (2015);DOI: 10.1016/j.ejmech.2015.12.025

C. C. Chen, M. Keller, M. Hess, R. Schiffmann, N. Urban, A. Wolfgardt, M. Schaefer, F. Bracher, M. Biel, C. Wahl-Schott, C. Grimm; A small molecule restores function to TRPML1 mutant isoforms responsible for mucolipidosis type IV; Nature Communications; (2014); DOI: 10.1038/ncomms5681

M. Krojer, M. Keller, F. Bracher; 7-Aza-des-A-steroids with antimicrobial and cytotoxic effects; Scientia Pharmaceutica, 81, 329-338 (2013)

S. Lange, M. Keller, C. Müller, S. Oliaro-Bosso, G. Balliano, F. Bracher; Aminopropylindenes derived from Grundmann's ketone as a novel chemotype of oxidosqualene cyclase inhibitors; Eur. J. Med. Chem. 63, 758-764 (2013)

P. Filippakopoulos, S. Picaud, O. Fedorov, M. Keller, M. Wrobel, O. Morgenstern, F. Bracher, S. Knapp; Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family; Bioorg. & Med. Chem. 20, 1878-1886 (2012)

L. Schiefelbein, M. Keller, F. Weissmann, M. Luber, F. Bracher, W. Frieß; Synthesis, characterization and assessment of suitability of trehalose fatty acid esters as alternatives for polysorbates in protein formulation; Eur. J. Pharm. Biopharm. 76, 342-350 (2010)

J. S. Mathieson, G. J. T. Cooper, A. L. Pickering, M. Keller, D. L. Long, G. N. Newton, L. Cronin; Monitoring the formation of coordination complexes using electrospray mass spectrometry; Chem. Asian J. 4, 681-687 (2009)

G. J. T. Cooper, G. N. Newton, D. L. Long, P. Koegerler, M. H. Rosnes, M. Keller, L. Cronin; Exploring a series of isostructural dodecanuclear mixed Ni:Co clusters: toward the control of elemental composition using pH and soichiometry; Inorg. Chem. 48, 1097-1104 (2009)



Vorträge


M. Keller, C. Müller, F. Bracher; Synthesis of new and selective inhibitors of human oxidosqualene cyclase; Jahrestagung der DPhG, 28.09. - 01.10.2009, Jena, Germany



Poster und Tagungsbeiträge 

M. Keller, A. Wolfgardt, C. Müller, S. Oliaro-Bosso, G, Balliano, R. Wilcken, F. Böckler, F. Bracher; Aryltetrahydropyridine and arylpiperidine derivatives as a new class of human oxidosqualene cyclase inhibitors; Jahrestagung der DPhG, 09.10.-11.10.2013, Freiburg, Germany

M. Wrobel, M. Keller, P.  Filippakopoulos, S. Knapp, F.Bracher; Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family; Frontiers in Medicinal Chemistry, 18.03.-20.03.2013, München, Germany

M. Worbel, M. Keller, P. Filippakopoulos, O. Morgenstern, S. Knapp, F.Bracher; Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family; Summer School, 26.09.-28.09.2013, Regensburg, Germany

A. Wolfgardt, Ch. Müller, M. Keller, F. Bracher; Synthesis of new selective oxidosqualene cyclase inhibitors; Joint Meeting of the Austrian and German Pharmaceutical Societies, 20.09. - 23.09.2011, Innsbruck, Austria

L. Schiefelbein, M. Keller, F. Weissmann, M. Luber, F. Bracher, W. Frieß; Synthesis, characterization and assessment of suitability of trehalose fatty acid esters as alternatives for polysorbates in protein formulation; DPhG International Graduate Student Symposium, 18.11. - 21.11.2009, Pichlarn, Austria

L. Schiefelbein, M. Keller, F. Bracher, W. Frieß; Relationship between hemolytic activity and critical micelle concentration (CMC) of sugar based surfactants for protein formulations; 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 07.04. - 10.04.2008, Barcelona, Spain



Kristallstrukturen

3U5L

Crystal Structure of the first bromodomain of human BRD4 in complex with a benzo-triazepine ligand (BzT-7)

Authors:    Filippakopoulos, P., Picaud, S., Felletar, I., Fedorov, O., Keller, M., Wrobel, M., Morgenstern, O., von Delft, F., Arrowsmith, C.H., Edwards, A.M., Weigelt, J., Bountra, C., Bracher, F., Knapp, S.

 

DOI:10.2210/pdb3u5l/pdb

PDB code: 3U5L



Forschung


Synthese selektiver Aktivatoren des TRPML1 Ionenkanals zur Behandlung der Mucolipidose IV.

Synthese von Verbindungsklassen (z.B. Benzodiazepine, Benzotriazepine), die als Inhibitoren von Bromodomains der BET-Familie fungieren.

Synthese von Substanzen, die Enzyme der Cholesterolbiosynthese hemmen (z.B. Oxidosqualencylcase-Inhibitoren) und somit als neue lipidsenkende Wirkstoffe in Frage kommen.



Kooperation

Prof. Dr. Stefan Knapp, Department of Clinical Medicine, Structural Genomics Consortium, University of Oxford (Kinase-Inhibitoren, Cokristallisationen)

Prof. Dr. Martin Biel, Dr. Dr. Christian Grimm, Ludwig-Maximilians-Universität München (Aktivatoren des TRPML1 Ionenkanals)

Prof. Dr. Frank Böckler, Institut Pharmazie, Universität Tübingen (Molecular Modelling)

Prof. Dr. Gianni Balliano, Universität Turin (Oxidosqualencyclase-Inhibitoren)



Lehre

Qualitative Bestimmung von Arznei-, Hilfs- und Schadstoffen unter Einbeziehung von Arzneibuchmethoden (Pharmazie Staatsexamen)

Qualitative anorganische Analytik (Pharmaceutical Sciences)